
CLADE is delighted to share a new addition to the leadership team.
Vinay brings deep expertise in mathematical modelling and data science, with a track record of building and deploying solutions that support biopharma workflows across R&D, Quality, Clinical, and Regulatory contexts.
Vinay said:
“I’m looking forward to shaping the data science strategy at CLADE. The goal is to deliver more reliable and actionable information from each measurement to our biopharma customers, faster, without them having to run the analysis themselves.”
CLADE CEO Dominik Sievert added:
“Data science is central to our road ahead. Our customers need answers, not raw output. Vinay’s background is exactly what is required to address this need.”

Related news
New Application Note: Rapid Detection of Sorbitol Adulteration
CLADE Announces Distribution Partnership with Guangdong DenLey Technology
New product introduction: CLADE™ Workbench
Upcoming webinar: Data-Driven UF/DF at Lab Scale (May 6, 2026)
CLADE strengthens global presence by welcoming US-based experts
Dr Maximilian B. Rauscher joins CLADE as Head of Revenue
Webinar Spotlight: Join our webinar in November
CLADE expands to the U.S.
New Product Launches: Sphere in a Box and our next QA Scan iteration
Discover more news from CLADE
New Application Note: Rapid Detection of Sorbitol Adulteration

CLADE Announces Distribution Partnership with Guangdong DenLey Technology

New product introduction: CLADE™ Workbench

Upcoming webinar: Data-Driven UF/DF at Lab Scale (May 6, 2026)

CLADE strengthens global presence by welcoming US-based experts

Dr Maximilian B. Rauscher joins CLADE as Head of Revenue

Webinar Spotlight: Join our webinar in November

CLADE expands to the U.S.

New Product Launches: Sphere in a Box and our next QA Scan iteration

Connect with CLADE
Inquire about a product
Request a quote, send us a sample for analysis or other inquiries.
Talk to an
expert
Schedule a call with a CLADE expert and discuss your needs.
Follow CLADE on LinkedIn
Join this community to keep updated on latest developments.
